Please note: Items that appear in the Community Postings section are submitted by visitors. Posts are reviewed to ensure they are appropriate for our audience, but typically are not edited by University Marketing and Communications.
The Case Comprehensive Cancer Center is hosting is quarterly scientific series Monday, June 4 from 5-7pm in the Iris S. and Bert L. Wolstein Research Building auditorium. The program will feature updates from recipients of VeloSano pilot awards. Presentations will be followed by a reception.
- Mark Jackson, PhD: "A high-throughput screen for inhibitors of cancer stem cell plasticity"
- Julian Kim, MD: "Development of intravenously injectable β-glucan treatment for regulating granulocytic myeloid-derived suppressive cells"
- Shigemi Matsuyama, PhD: "Development of new type of therapeutics selectively targeting Bax or Bak"
- Alvin Schmaier, MD: "Tyrosine kinase inhibitors and cardiovascular events in CML"
- Andrew Sloan, MD: "Hematologic biomarkers of treatment response & recurrence in patients with glioblastoma"
- Zhenghe John Wang, PhD: "Develop GPT2 inhibitors to target PI3KCA-mutated colorectal cancers"
- Youwei Zhang, PhD: "Roles of UbcH7 in tumorigenesis and therapy response"
- Lan Zhou, MD, PhD: "Mediates immune-suppressive microenvironment in serrated pathway of colon carcinogenesis"